

Corporate Data

MalVa (Formation due July 2010)
c/o Department of Infectious Diseases
Im Neuenheimer Feld 324
69120 Heidelberg
info@malvacompany.de
Contact: Dr. Kirsten Heiß
Tel. +49 (6221)568284 - k.heiss@malvacompany.de



Core Team and Responsibilities

Dr. Kirsten Heiß: scientific management
Dr. Ann-Kristin Müller: scientific advisor
Dr. med. Johannes Pfeil: clinical management
Dr. Marcus Furch, MBA: business development advisor
Dipl. Biol. Florian Kohlhepp: antigen identification
Dipl. Biol. Roland Frank: vaccine prototype production
M.Sc. Matthew Lewis: vaccine prototype testing



From left to right: K. Heiß, A.-K. Müller, R. Frank, F. Kohlhepp, J. Pfeil, M. Lewis

Technologies and Intellectual Properties

- The MalVa team has developed a new strategy to identify malaria vaccine candidate proteins
- The patent for the most advanced candidate protein is currently pending. Patent application has been made through the University of Heidelberg. MalVa will have full ownership or alternatively exclusive rights to this patent (currently under negotiation)
- Patent applications for further candidates are under preparation

Business Model, Market Strategies, Competitors

- At the first stage, MalVa specialises in malaria vaccine development employing a novel antigen that is currently tested in immunological studies
- We aim to develop the vaccine candidate towards a phase II clinical trial. Collaborative development and licensing agreements with an experienced pharmaceutical company will bring the product to the market
- The market for a successful malaria vaccine includes people living in endemic countries as well as business people, military and tourists travelling to endemic countries. The market size for a successful malaria vaccine would be around 1 billion USD/ year (BCG, 2005)
- So far, there is no approved malaria vaccine on the market. There are several early stage developments. The most advanced development by GlaxoSmithKline is currently undergoing phase III clinical trials. However, this development only offers weak protection against malaria and better vaccines are urgently needed. MalVa strives to achieve this

Current Status

- The team is currently funded through the Exist-Forschungstransfer EXIST
- The MalVa company is going to be founded by July 2010 (seven shareholders)
- The interdisciplinary MalVa team combines experience in Science, Medicine and Business Development
- The most advanced candidate antigen is currently evaluated in immunological studies
- Future steps include a phase I clinical trial (planned for 2012)

Offers and Requests

- **Financing:** we are currently looking for seed investors (total investment 1 million Euro in order to finalise the pre-clinical phase)
- **Business Development:** we are looking for collaborators in the field of vaccine development and specifically interested in additional adjuvant systems for vaccine formulation. We are eager to apply our expertise to other early stage vaccine development approaches